The Antifungal That Actually Fits His Week, Not Just His Culture Result
A single patient, whose regimen finally worked not because the drug changed, but because someone checked his actual week before choosing it.
K.D., a 46-year-old man, is four months into recovery from injection drug use, engaged weekly with an outpatient addiction medicine program he describes, without much prompting, as the first structure that has actually held for him. This is his fourth candidemia episode this year, and the current isolate — Candida glabrata again, but this time confirmed fully echinocandin-susceptible on testing, unlike a resistant strain — is not the hard part of his case. The hard part, twice already this year, has been finishing outpatient treatment at all: years of injection use have left his peripheral venous access extensively scarred, and daily IV infusions, the standard completion regimen, simply haven't been available to him outside the hospital. Not from unwillingness — both prior attempts ended because reliable daily access genuinely wasn't there, and his housing situation, only now stabilizing after a period of real instability, has never included home health nursing coverage.
Once his acute infection is controlled this admission, the actual clinical question is which outpatient completion strategy can plausibly work for him, not just which one clears the organism on paper. Standard step-down to oral fluconazole is a weaker fit here on its own pharmacologic terms — glabrata carries intrinsically reduced fluconazole susceptibility even when technically testing susceptible, the same limitation raised in a different patient's care earlier this same volume. Daily IV echinocandin, the usual strong alternative, is exactly the regimen he has already failed twice, for reasons that have nothing to do with the drug's effectiveness. Rezafungin's once-weekly IV dosing — built on a structural modification that extends its half-life well beyond older echinocandins, enabling that weekly interval — is a genuine practical answer to a barrier that is about access frequency, not about whether IV therapy itself is acceptable to him. The ReSTORE trial established it as non-inferior to caspofungin in candidemia and invasive candidiasis, which is the disease he actually has; what ReSTORE did not enroll is a population defined by the thing that has twice defeated him, since its patients were hospitalized and dosed on protocol rather than depending on a weekly outpatient visit to receive the drug at all. His four months of unbroken program attendance is the closest thing anyone has to evidence that the interval will hold in him, and it is his own record rather than a trial's.
Before discharge, matching the regimen to the actual calendar
The ReSTORE trial established rezafungin as non-inferior to caspofungin for candidemia and invasive candidiasis specifically — real invasive-disease evidence, not just a promising mechanism. Weekly dosing directly answers his documented barrier, which is access frequency, not IV therapy itself. I'd start it as his outpatient completion regimen.
Before we finalize that, I want to check something concrete rather than assume it — his program already has a structured weekly visit day, and he's attended every single one for four months. If we anchor his infusion to that existing day, we're not asking him to build a new habit around this, we're attaching it to one that's already holding. That actually strengthens your case rather than complicating it.
Worth naming honestly, not to override the plan but so it's an informed choice: ibrexafungerp's oral route looks appealing given everything just discussed, but its invasive-candidiasis evidence remains genuinely thin — small early-phase data, with its actual FDA approval scoped to vulvovaginal candidiasis, not this disease. That's a real evidence gap, not a knock on the drug in general.
Where I'd push back on the plan itself is the part being treated as its strength. Anchoring a seven-day dosing interval to a single weekly appointment means one missed visit isn't a late dose, it's a doubled interval — and rezafungin's front-loaded schedule tolerates that far better in week one, when a 400mg dose is on board, than in week four. A daily regimen degrades gracefully when a dose is missed; this one doesn't. That's an argument for building the fallback now, while he's still inpatient, not an argument against the drug.
Agreed: rezafungin selected as his outpatient completion regimen, first weekly dose given inpatient before discharge and the second anchored directly to his existing weekly addiction-program visit day, with the infusion coordinated at that same clinic rather than a separate appointment.
Fully resolved, and explicitly credited in the discharge note as the actual turning point in his care: the plan changed for the better once his real schedule was checked directly rather than assumed, a point the addiction medicine specialist asked to have documented plainly so it isn't lost in the pharmacology discussion alone.